Narcotrend Versus Bispectral Index Monitoring During Sufentanil-Midazolam Anesthesia for Bronchoscopy

• Status: Completed
• Trial end date: 2019-01-30
• Target enrollment: 0
• Participant gender: All

Summary

This study was aimed to determine whether narcotrend monitoring was better than bispectral index monitoring during sufentanil-midazolam anesthesia for bronchoscopy under conscious sedation. Patients were randomised to receive Narcotrend, Bispectral Index(BIS) monitoring or without monitoring. Midazolam was given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by the narcotrend index (NI; B and C) or bispectral index (BIS; between 70 and 85) or according to patient's tolerance assessed by physician . The primary end-point was dosage of midazolam. Other end-points included adverse events, patient tolerance and physician satisfaction.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Guangzhou Institute of Respiratory Disease
• Treatments: Anesthetics; Lidocaine; Midazolam; Sufentanil

Criteria

Inclusion Criteria:

ASA grade I-II

Exclusion Criteria:

1. psychological disorders

2. SpO2<90% in ambient air

3. hypersensitivity or allergy to anaesthetic drugs or benzodiazepine

4. severe chronic obstructive pulmonary disease (forced expiratory volume in 1 s ,50% of predicted value, requirement for oxygen therapy)

5. unstable haemodynamic status

6. habitual alcohol consumption